SCHEDULE OF SEGMENT REPORTING INFORMATION BY SEGMENT (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Revenues: | ||||||||
| Rental income | $ 3,756,368 | $ 4,281,753 | $ 7,440,412 | $ 8,314,182 | $ 16,470,918 | $ 18,523,813 | ||
| Fees and other income | 58,707 | 96,987 | 147,463 | 189,743 | 343,790 | 401,462 | ||
| Total revenue | 3,815,075 | 4,378,740 | 7,587,875 | 8,503,925 | 16,814,708 | 18,925,275 | ||
| Costs and expenses: | ||||||||
| Rental operating costs | 1,258,664 | 1,462,605 | 2,803,105 | 3,075,248 | 6,158,052 | 6,256,077 | ||
| General and administrative | 1,341,297 | 1,223,658 | 3,015,120 | 2,885,634 | 5,704,830 | 7,526,675 | ||
| Depreciation and amortization | 898,710 | 1,211,691 | 1,897,679 | 2,455,796 | 4,862,267 | 5,515,518 | ||
| Impairment of goodwill and real estate assets | 2,978,150 | 4,317,389 | 3,502,523 | 4,344,332 | 6,443,437 | 1,969,311 | ||
| Total costs and expenses | 6,476,821 | 8,215,343 | 11,218,427 | 12,761,010 | 23,168,586 | 21,267,581 | ||
| Other income (expense): | ||||||||
| Interest expense - mortgage notes | (1,151,932) | (1,477,870) | (3,202,006) | (2,988,341) | (6,050,437) | (6,050,196) | ||
| Interest and other income, net | 5,206 | 5,206 | 10,355 | 10,354 | 20,881 | (151,356) | ||
| Net gain in Conduit Pharmaceuticals marketable securities (see footnote 9) | 5,743 | (7,802) | 7,728 | (184,459) | (188,287) | (17,925,723) | ||
| Gain on sales of real estate, net | (21,997) | 323,359 | 150,099 | 4,777,327 | 5,444,792 | 3,426,572 | ||
| Gain on disposition of assets and liabilities, net | 3,416,501 | |||||||
| Income tax (expense) benefit | (26,630) | (53,910) | (44,687) | (28,501) | (463,170) | (60,855) | ||
| Total other income, net | (1,189,610) | (1,211,017) | 337,990 | 1,586,380 | (1,236,221) | (20,761,558) | ||
| Net income (loss) | (3,851,356) | $ 558,794 | (5,047,620) | $ 2,376,915 | (3,292,562) | (2,670,705) | (7,590,099) | (23,103,864) |
| Less: Income attributable to noncontrolling interests | 40,230 | (228,905) | (77,655) | (340,468) | (685,586) | (2,524,665) | ||
| Net income (loss) attributable to Presidio Property Trust, Inc. stockholders | (3,811,126) | (5,276,525) | (3,370,217) | (3,011,173) | (8,275,685) | (25,628,529) | ||
| Operating Segments [Member] | Retail Properties [Member] | ||||||||
| Revenues: | ||||||||
| Rental income | 93,574 | 93,574 | 187,148 | 356,452 | 543,600 | 2,058,622 | ||
| Fees and other income | 400 | 400 | 62,041 | |||||
| Total revenue | 93,574 | 93,574 | 187,148 | 356,852 | 544,000 | 2,120,663 | ||
| Costs and expenses: | ||||||||
| Rental operating costs | 5,261 | 4,824 | 10,093 | 105,392 | 115,047 | 608,667 | ||
| General and administrative | ||||||||
| Depreciation and amortization | 22,928 | 22,928 | 45,856 | 54,617 | 100,472 | 394,461 | ||
| Impairment of goodwill and real estate assets | ||||||||
| Total costs and expenses | 28,189 | 27,752 | 55,949 | 160,009 | 215,519 | 1,003,128 | ||
| Other income (expense): | ||||||||
| Interest expense - mortgage notes | (38,728) | (39,942) | (81,845) | (198,039) | (276,961) | (577,761) | ||
| Interest and other income, net | ||||||||
| Net gain in Conduit Pharmaceuticals marketable securities (see footnote 9) | ||||||||
| Gain on sales of real estate, net | 4,213,068 | 4,494,358 | ||||||
| Gain on disposition of assets and liabilities, net | ||||||||
| Income tax (expense) benefit | ||||||||
| Total other income, net | (38,728) | (39,942) | (81,845) | 4,015,029 | 4,217,397 | (577,761) | ||
| Net income (loss) | 26,657 | 25,880 | 49,354 | 4,211,872 | 4,545,878 | 539,774 | ||
| Less: Income attributable to noncontrolling interests | ||||||||
| Net income (loss) attributable to Presidio Property Trust, Inc. stockholders | 26,657 | 25,880 | 49,354 | 4,211,872 | 4,545,878 | 539,774 | ||
| Operating Segments [Member] | Office Industrial Properties [Member] | ||||||||
| Revenues: | ||||||||
| Rental income | 2,846,734 | 3,168,878 | 5,517,315 | 6,022,908 | 11,975,156 | 12,097,022 | ||
| Fees and other income | 51,316 | 64,893 | 134,115 | 127,255 | 257,414 | 241,530 | ||
| Total revenue | 2,898,050 | 3,233,771 | 5,651,430 | 6,150,163 | 12,232,570 | 12,338,552 | ||
| Costs and expenses: | ||||||||
| Rental operating costs | 1,323,387 | 1,549,497 | 2,954,224 | 3,167,862 | 6,423,862 | 6,136,564 | ||
| General and administrative | 20 | 17,519 | 16,850 | 19,195 | 2,330 | |||
| Depreciation and amortization | 694,602 | 955,575 | 1,478,878 | 1,954,744 | 3,910,547 | 4,154,769 | ||
| Impairment of goodwill and real estate assets | 2,833,462 | 4,226,620 | 3,282,197 | 4,226,620 | 6,031,828 | 1,377,937 | ||
| Total costs and expenses | 4,851,471 | 6,731,692 | 7,732,818 | 9,366,076 | 16,385,432 | 11,671,600 | ||
| Other income (expense): | ||||||||
| Interest expense - mortgage notes | (670,352) | (921,953) | (2,213,435) | (1,813,284) | (3,757,328) | (3,457,360) | ||
| Interest and other income, net | (171,734) | |||||||
| Net gain in Conduit Pharmaceuticals marketable securities (see footnote 9) | ||||||||
| Gain on sales of real estate, net | ||||||||
| Gain on disposition of assets and liabilities, net | 3,416,501 | |||||||
| Income tax (expense) benefit | (2,000) | (2,000) | (9,600) | |||||
| Total other income, net | (672,352) | (921,953) | 1,201,066 | (1,813,284) | (3,766,928) | (3,629,094) | ||
| Net income (loss) | (2,625,773) | (4,419,874) | (880,322) | (5,029,197) | (7,919,790) | (2,962,142) | ||
| Less: Income attributable to noncontrolling interests | (11,438) | (11,655) | (9,385) | (29,614) | (47,710) | (86,686) | ||
| Net income (loss) attributable to Presidio Property Trust, Inc. stockholders | (2,637,211) | (4,431,529) | (889,707) | (5,058,811) | (7,967,500) | (3,048,828) | ||
| Operating Segments [Member] | Model Home Properties [Member] | ||||||||
| Revenues: | ||||||||
| Rental income | 816,060 | 1,019,301 | 1,735,949 | 1,934,822 | 3,952,162 | 4,368,169 | ||
| Fees and other income | 512 | 428 | 6,047 | (1,326) | 5,776 | 68,084 | ||
| Total revenue | 816,572 | 1,019,729 | 1,741,996 | 1,933,496 | 3,957,938 | 4,436,253 | ||
| Costs and expenses: | ||||||||
| Rental operating costs | 42,064 | 49,940 | 90,941 | 98,097 | 212,817 | 171,621 | ||
| General and administrative | 225,959 | 187,935 | 452,842 | 417,895 | 813,705 | 820,217 | ||
| Depreciation and amortization | 180,707 | 231,954 | 371,998 | 443,967 | 846,818 | 952,627 | ||
| Impairment of goodwill and real estate assets | 144,688 | 90,769 | 220,326 | 117,712 | 339,609 | 406,374 | ||
| Total costs and expenses | 593,418 | 560,598 | 1,136,107 | 1,077,671 | 2,212,949 | 2,350,839 | ||
| Other income (expense): | ||||||||
| Interest expense - mortgage notes | (441,573) | (514,636) | (904,131) | (974,346) | (2,010,791) | (2,009,641) | ||
| Interest and other income, net | 8 | 8 | 15 | 15 | (13,735) | (23,890) | ||
| Net gain in Conduit Pharmaceuticals marketable securities (see footnote 9) | ||||||||
| Gain on sales of real estate, net | (21,997) | 323,359 | 150,099 | 564,259 | 950,434 | 3,426,572 | ||
| Gain on disposition of assets and liabilities, net | ||||||||
| Income tax (expense) benefit | (3,630) | (30,310) | (19,287) | (52,481) | (60,875) | (55,543) | ||
| Total other income, net | (467,192) | (221,579) | (773,304) | (462,553) | (1,134,967) | 1,337,498 | ||
| Net income (loss) | (244,038) | 237,552 | (167,415) | 393,272 | 610,022 | 3,422,912 | ||
| Less: Income attributable to noncontrolling interests | 51,668 | (217,250) | (68,270) | (310,854) | (637,876) | (2,437,979) | ||
| Net income (loss) attributable to Presidio Property Trust, Inc. stockholders | (192,370) | 20,302 | (235,685) | 82,418 | (27,854) | 984,933 | ||
| Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | ||||||||
| Revenues: | ||||||||
| Rental income | ||||||||
| Fees and other income | 6,879 | 31,666 | 7,301 | 63,414 | 80,200 | 29,807 | ||
| Total revenue | 6,879 | 31,666 | 7,301 | 63,414 | 80,200 | 29,807 | ||
| Costs and expenses: | ||||||||
| Rental operating costs | (112,048) | (141,656) | (252,153) | (296,103) | (593,674) | (660,775) | ||
| General and administrative | 1,115,318 | 1,035,723 | 2,544,759 | 2,450,889 | 4,871,930 | 6,704,128 | ||
| Depreciation and amortization | 473 | 1,234 | 947 | 2,468 | 4,430 | 13,661 | ||
| Impairment of goodwill and real estate assets | 72,000 | 185,000 | ||||||
| Total costs and expenses | 1,003,743 | 895,301 | 2,293,553 | 2,157,254 | 4,354,686 | 6,242,014 | ||
| Other income (expense): | ||||||||
| Interest expense - mortgage notes | (1,279) | (1,339) | (2,595) | (2,672) | (5,357) | (5,434) | ||
| Interest and other income, net | 5,198 | 5,198 | 10,340 | 10,339 | 34,616 | 44,268 | ||
| Net gain in Conduit Pharmaceuticals marketable securities (see footnote 9) | 5,743 | (7,802) | 7,728 | (184,459) | (188,287) | (17,925,723) | ||
| Gain on sales of real estate, net | ||||||||
| Gain on disposition of assets and liabilities, net | ||||||||
| Income tax (expense) benefit | (21,000) | (23,600) | (23,400) | 23,980 | (392,695) | (5,312) | ||
| Total other income, net | (11,338) | (27,543) | (7,927) | (152,812) | (551,723) | (17,892,201) | ||
| Net income (loss) | (1,008,202) | (891,178) | (2,294,179) | (2,246,652) | (4,826,209) | (24,104,408) | ||
| Less: Income attributable to noncontrolling interests | ||||||||
| Net income (loss) attributable to Presidio Property Trust, Inc. stockholders | $ (1,008,202) | $ (891,178) | $ (2,294,179) | $ (2,246,652) | $ (4,826,209) | $ (24,104,408) | ||